KR20150038241A - Jak/stat 억제제에 대한 치료 반응의 예측 - Google Patents
Jak/stat 억제제에 대한 치료 반응의 예측 Download PDFInfo
- Publication number
- KR20150038241A KR20150038241A KR20157004583A KR20157004583A KR20150038241A KR 20150038241 A KR20150038241 A KR 20150038241A KR 20157004583 A KR20157004583 A KR 20157004583A KR 20157004583 A KR20157004583 A KR 20157004583A KR 20150038241 A KR20150038241 A KR 20150038241A
- Authority
- KR
- South Korea
- Prior art keywords
- jak
- stat
- cish
- inhibitor
- socs2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 93
- 238000011282 treatment Methods 0.000 title claims abstract description 48
- 230000004044 response Effects 0.000 title claims description 8
- 101100366892 Anopheles gambiae Stat gene Proteins 0.000 title 1
- 101100366894 Drosophila melanogaster Stat92E gene Proteins 0.000 title 1
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 claims abstract description 106
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 claims abstract description 106
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 claims abstract description 106
- 238000000034 method Methods 0.000 claims abstract description 68
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 35
- 201000011510 cancer Diseases 0.000 claims abstract description 27
- 230000014509 gene expression Effects 0.000 claims description 112
- 239000000090 biomarker Substances 0.000 claims description 90
- 239000000523 sample Substances 0.000 claims description 43
- 108020004999 messenger RNA Proteins 0.000 claims description 40
- 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 claims description 26
- 101000943420 Homo sapiens Cytokine-inducible SH2-containing protein Proteins 0.000 claims description 26
- 101000687808 Homo sapiens Suppressor of cytokine signaling 2 Proteins 0.000 claims description 23
- 102100024784 Suppressor of cytokine signaling 2 Human genes 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 20
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims description 18
- 102100027641 DNA-binding protein inhibitor ID-1 Human genes 0.000 claims description 16
- 101001081590 Homo sapiens DNA-binding protein inhibitor ID-1 Proteins 0.000 claims description 16
- 101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 claims description 16
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 claims description 16
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 claims description 16
- 102100035405 Neutrophil gelatinase-associated lipocalin Human genes 0.000 claims description 16
- 239000012472 biological sample Substances 0.000 claims description 15
- 230000002489 hematologic effect Effects 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 13
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 10
- -1 IDl Proteins 0.000 claims description 10
- 101001049697 Homo sapiens Early growth response protein 1 Proteins 0.000 claims description 9
- 206010025323 Lymphomas Diseases 0.000 claims description 9
- 208000032839 leukemia Diseases 0.000 claims description 9
- 102100023226 Early growth response protein 1 Human genes 0.000 claims description 8
- 238000005259 measurement Methods 0.000 claims description 8
- CVYIPHUZLMREPA-OAHLLOKOSA-N C1(CCCC1)[C@@H](CC#N)N1N=CC(=C1)C=1N=CC2=C(N1)NC=C2 Chemical group C1(CCCC1)[C@@H](CC#N)N1N=CC(=C1)C=1N=CC2=C(N1)NC=C2 CVYIPHUZLMREPA-OAHLLOKOSA-N 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 201000005787 hematologic cancer Diseases 0.000 claims description 5
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 5
- 230000005540 biological transmission Effects 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000004043 responsiveness Effects 0.000 claims description 2
- 238000011287 therapeutic dose Methods 0.000 claims description 2
- 102100031955 Lon protease homolog, mitochondrial Human genes 0.000 claims 7
- 239000000556 agonist Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 76
- 102000042838 JAK family Human genes 0.000 description 55
- 108091082332 JAK family Proteins 0.000 description 55
- 210000004027 cell Anatomy 0.000 description 38
- 125000000217 alkyl group Chemical group 0.000 description 26
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 23
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 22
- 125000003118 aryl group Chemical group 0.000 description 21
- 125000001072 heteroaryl group Chemical group 0.000 description 21
- 125000000753 cycloalkyl group Chemical group 0.000 description 20
- 230000019491 signal transduction Effects 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 125000003710 aryl alkyl group Chemical group 0.000 description 17
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 16
- 238000009396 hybridization Methods 0.000 description 16
- 238000012340 reverse transcriptase PCR Methods 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
- 230000011664 signaling Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 11
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 11
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 11
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 11
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 11
- 125000005843 halogen group Chemical group 0.000 description 11
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 11
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 238000001574 biopsy Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 7
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000010606 normalization Methods 0.000 description 6
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 6
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
- 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- 102100026031 Beta-glucuronidase Human genes 0.000 description 3
- 108700039887 Essential Genes Proteins 0.000 description 3
- 101000933465 Homo sapiens Beta-glucuronidase Proteins 0.000 description 3
- 101150033052 MAS5 gene Proteins 0.000 description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
- 101100344462 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YDJ1 gene Proteins 0.000 description 3
- 102000000887 Transcription factor STAT Human genes 0.000 description 3
- 108050007918 Transcription factor STAT Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 208000014951 hematologic disease Diseases 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000002853 nucleic acid probe Substances 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 101150101112 7 gene Proteins 0.000 description 2
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 2
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 2
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 2
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 2
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 101150117538 Set2 gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 201000008736 Systemic mastocytosis Diseases 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 2
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 2
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 2
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 2
- 208000017733 acquired polycythemia vera Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 125000004966 cyanoalkyl group Chemical group 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000003500 gene array Methods 0.000 description 2
- 230000004547 gene signature Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000037244 polycythemia vera Diseases 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 2
- 229960000215 ruxolitinib Drugs 0.000 description 2
- 238000011301 standard therapy Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- JCLFHZLOKITRCE-UHFFFAOYSA-N 4-pentoxyphenol Chemical compound CCCCCOC1=CC=C(O)C=C1 JCLFHZLOKITRCE-UHFFFAOYSA-N 0.000 description 1
- 101150095412 47 gene Proteins 0.000 description 1
- YVXHGUNTDXWPJV-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine-2-carbonitrile Chemical compound N1C(C#N)=NC=C2C=CN=C21 YVXHGUNTDXWPJV-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000005431 Endometrioid Carcinoma Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 230000035986 JAK-STAT signaling Effects 0.000 description 1
- 101150009057 JAK2 gene Proteins 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- 201000003791 MALT lymphoma Diseases 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000009277 Neuroectodermal Tumors Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000006467 TATA-Box Binding Protein Human genes 0.000 description 1
- 108010044281 TATA-Box Binding Protein Proteins 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 238000011979 disease modifying therapy Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 208000028730 endometrioid adenocarcinoma Diseases 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 238000007387 excisional biopsy Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000005861 gene abnormality Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 230000009033 hematopoietic malignancy Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000010810 high throughput mRNA sequencing Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000012296 in situ hybridization assay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 208000006971 mastocytoma Diseases 0.000 description 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 239000000088 plastic resin Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- VIXWGKYSYIBATJ-UHFFFAOYSA-N pyrrol-2-one Chemical compound O=C1C=CC=N1 VIXWGKYSYIBATJ-UHFFFAOYSA-N 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261676484P | 2012-07-27 | 2012-07-27 | |
| US61/676,484 | 2012-07-27 | ||
| US201361769271P | 2013-02-26 | 2013-02-26 | |
| US61/769,271 | 2013-02-26 | ||
| US201361829327P | 2013-05-31 | 2013-05-31 | |
| US61/829,327 | 2013-05-31 | ||
| PCT/US2013/051824 WO2014018632A1 (en) | 2012-07-27 | 2013-07-24 | Prediction of treatment response to jak/stat inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150038241A true KR20150038241A (ko) | 2015-04-08 |
Family
ID=48906529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR20157004583A Withdrawn KR20150038241A (ko) | 2012-07-27 | 2013-07-24 | Jak/stat 억제제에 대한 치료 반응의 예측 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20150299796A1 (enExample) |
| EP (1) | EP2877596A1 (enExample) |
| JP (1) | JP2015526074A (enExample) |
| KR (1) | KR20150038241A (enExample) |
| CN (1) | CN104508149A (enExample) |
| AU (2) | AU2013295855A1 (enExample) |
| BR (1) | BR112015001521A2 (enExample) |
| CA (1) | CA2880198A1 (enExample) |
| CL (1) | CL2015000192A1 (enExample) |
| HK (1) | HK1205198A1 (enExample) |
| IL (1) | IL236897A0 (enExample) |
| MX (1) | MX2015001269A (enExample) |
| PH (1) | PH12015500169A1 (enExample) |
| RU (1) | RU2015106714A (enExample) |
| SG (1) | SG11201500261VA (enExample) |
| TN (1) | TN2015000019A1 (enExample) |
| TW (1) | TW201409030A (enExample) |
| WO (1) | WO2014018632A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| CA2935423C (en) | 2014-01-24 | 2023-11-07 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
| AU2015210750B2 (en) | 2014-01-31 | 2020-08-20 | Children's Medical Center Corporation | Antibody molecules to TIM-3 and uses thereof |
| WO2015138920A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| WO2016040882A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of egfr inhibitors |
| KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| JO3746B1 (ar) | 2015-03-10 | 2021-01-31 | Aduro Biotech Inc | تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون" |
| ES2878188T3 (es) | 2015-07-29 | 2021-11-18 | Novartis Ag | Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3 |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| CN106544414A (zh) * | 2016-10-09 | 2017-03-29 | 广州泰诺迪生物科技有限公司 | 一种检测肺癌脑转移样本中stat3和lck的方法 |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| CN107137701B (zh) * | 2017-05-07 | 2020-07-14 | 山东兴瑞生物科技有限公司 | 一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5424186A (en) | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
| US20060194275A1 (en) * | 2001-04-13 | 2006-08-31 | Incyte Corporation | Transporter and ion channels |
| EP2350317A4 (en) * | 2008-10-20 | 2012-06-27 | Univ Colorado Regents | BIOLOGICAL MARKERS FOR PREDICTING THE ANTICIPATE RESPONSE TO INSULINARY GROWTH FACTOR 1 RECEPTOR KINASE INHIBITORS |
| NZ597140A (en) * | 2009-06-05 | 2014-01-31 | Cephalon Inc | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives |
| WO2012071612A1 (en) * | 2010-12-03 | 2012-06-07 | Ym Biosciences Australia Pty Ltd | Treatment of jak2-mediated conditions |
-
2013
- 2013-07-24 SG SG11201500261VA patent/SG11201500261VA/en unknown
- 2013-07-24 AU AU2013295855A patent/AU2013295855A1/en not_active Abandoned
- 2013-07-24 RU RU2015106714A patent/RU2015106714A/ru not_active Application Discontinuation
- 2013-07-24 US US14/417,632 patent/US20150299796A1/en not_active Abandoned
- 2013-07-24 MX MX2015001269A patent/MX2015001269A/es unknown
- 2013-07-24 CN CN201380040005.0A patent/CN104508149A/zh active Pending
- 2013-07-24 BR BR112015001521A patent/BR112015001521A2/pt not_active IP Right Cessation
- 2013-07-24 CA CA2880198A patent/CA2880198A1/en not_active Abandoned
- 2013-07-24 JP JP2015524417A patent/JP2015526074A/ja active Pending
- 2013-07-24 EP EP13742819.9A patent/EP2877596A1/en not_active Withdrawn
- 2013-07-24 KR KR20157004583A patent/KR20150038241A/ko not_active Withdrawn
- 2013-07-24 WO PCT/US2013/051824 patent/WO2014018632A1/en not_active Ceased
- 2013-07-24 HK HK15105427.5A patent/HK1205198A1/xx unknown
- 2013-07-26 TW TW102126993A patent/TW201409030A/zh unknown
-
2015
- 2015-01-16 TN TNP2015000019A patent/TN2015000019A1/fr unknown
- 2015-01-22 IL IL236897A patent/IL236897A0/en unknown
- 2015-01-26 CL CL2015000192A patent/CL2015000192A1/es unknown
- 2015-01-26 PH PH12015500169A patent/PH12015500169A1/en unknown
-
2017
- 2017-07-14 AU AU2017204894A patent/AU2017204894A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TN2015000019A1 (en) | 2016-06-29 |
| MX2015001269A (es) | 2015-05-08 |
| AU2013295855A1 (en) | 2015-02-12 |
| SG11201500261VA (en) | 2015-02-27 |
| TW201409030A (zh) | 2014-03-01 |
| CA2880198A1 (en) | 2014-01-30 |
| WO2014018632A1 (en) | 2014-01-30 |
| JP2015526074A (ja) | 2015-09-10 |
| BR112015001521A2 (pt) | 2017-11-07 |
| CL2015000192A1 (es) | 2015-06-26 |
| PH12015500169A1 (en) | 2015-03-16 |
| HK1205198A1 (en) | 2015-12-11 |
| EP2877596A1 (en) | 2015-06-03 |
| CN104508149A (zh) | 2015-04-08 |
| AU2017204894A1 (en) | 2017-08-03 |
| US20150299796A1 (en) | 2015-10-22 |
| RU2015106714A (ru) | 2016-09-20 |
| IL236897A0 (en) | 2015-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20150299796A1 (en) | Prediction of treatment response to jak/stat inhibitor | |
| Ricarte-Filho et al. | Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1 | |
| EP2715366B1 (en) | Biomarkers for hedgehog inhibitor therapy | |
| US20190345558A1 (en) | Method for determining sensitivity to a cdk4/6 inhibitor | |
| EP2711433B1 (en) | Method for predicting effectiveness of angiogenesis inhibitor | |
| JP2023054163A (ja) | 融合遺伝子及び／又はエクソンスキッピングにより生ずる転写産物を検出するためのプローブ及び方法 | |
| US11118232B2 (en) | Methods of detecting DDR2 mutations | |
| US20190256930A1 (en) | Biomarkers for determining responsiveness to lsd1 inhibitors | |
| EP3321377B1 (en) | Method for determining sensitivity to simultaneous inhibitor against parp and tankyrase | |
| WO2010073721A1 (ja) | ＭｉｃｒｏＲＮＡによる直腸癌に対する術前化学放射線療法の効果予測 | |
| Craddock et al. | Genomic pathology of lung cancer | |
| JP2011160678A (ja) | 検体を提供する哺乳動物における肝臓腫瘍性病変の存在を検出するために有効なマイクロｒｎａ | |
| IT201900000130A1 (it) | Metodo per identificare soggetti resistenti al trattamento con farmaci a base di platino e relativo kit | |
| JP2011160680A (ja) | 検体を提供する哺乳動物における肝臓腫瘍性病変の存在を検出するために有効なマイクロｒｎａ | |
| JP2011160677A (ja) | 検体を提供する哺乳動物における肝臓腫瘍性病変の存在を検出するために有効なマイクロｒｎａ | |
| JP2011160679A (ja) | 検体を提供する哺乳動物における肝臓腫瘍性病変の存在を検出するために有効なマイクロｒｎａ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20150224 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |